Summary of the Key Points
Wenzhou has initiated the first “non-recourse factoring” transaction in China that utilizes drug traceability codes: pharmaceutical companies sell accounts receivable (money owed by hospitals) to banks, receiving cash in advance. The banks have no right to seek repayment from the companies, meaning they bear the risk themselves. The key lies in using drug traceability codes to verify the authenticity of the transactions, with medical insurance playing a role in the verification process. This solution addresses the challenges faced by pharmaceutical companies in obtaining financing and the concerns of banks about potential risks. It also encourages more institutions to scan the codes, representing a win-win situation for all involved parties.
What is this “non-recourse factoring” exactly?
In simple terms, pharmaceutical companies in need of funds face long payment periods from hospitals. They sell the money owed to them by hospitals to banks to get cash upfront. For example, Sinopharm Holdings Wenzhou Company transferred the unpaid accounts receivable from an ophthalmology hospital to the Wenzhou branch of China Merchants Bank and received 9.21 million yuan in return.
The “non-recourse” aspect is crucial: if the hospital fails to pay, the bank cannot seek repayment from the pharmaceutical company, and the risk remains with the bank. Previously, banks were hesitant to engage in such transactions due to concerns about potential fraud. However, the use of drug traceability codes has resolved this issue by providing a means to verify the authenticity of the transactions.
Why do banks dare to take on this risk?
Drug traceability codes act as a reliable verification mechanism. Banks are most concerned about fraudulent transactions, such as pharmaceutical companies forging contracts with hospitals to obtain loans. In this case, the Wenzhou Medical Insurance Bureau used these codes to ensure the legitimacy of the transactions:
1. Full-chain verification: The medical insurance system can access all traceability code data, covering every step from drug production and distribution to hospital receipt. Over 130,000 codes were checked in this instance, confirming that the drugs were genuine, delivered correctly, and actually received by the hospitals.
2. Data security: Banks only see the “trusted results” provided by the medical insurance system, ensuring both accuracy and privacy protection.
3. Closed-loop validation: From the application for financing to the disbursement of funds, traceability codes are used throughout the process to ensure that each payment corresponds to a real drug transaction.
A lifesaver for pharmaceutical companies
This innovation significantly alleviates their difficulties:
- Long payment periods: Hospitals may take months to settle payments, locking up capital and preventing its circulation.
- Difficulties in financing: Without collateral, banks are reluctant to lend.
- Time-consuming account reconciliation: Reconciling accounts with hospitals is a cumbersome process.
With this new system, the lengthy offline verification steps are eliminated, allowing for quick disbursements. Pharmaceutical companies can use the funds to purchase more drugs and distribute them to grassroots hospitals, thereby expanding their business.
A win-win situation for all parties
- Companies: They can obtain financing using genuine transaction data without the need for collateral, solving the problem of slow payment collection.
- Banks: With traceability codes as proof, they are less prone to fraud and can explore new business opportunities in the pharmaceutical industry (e.g., China Merchants Bank granted a credit line of 300 million yuan).
- Medical insurance: The more widespread use of code scanning makes it easier for companies to obtain financing, motivating hospitals and pharmacies to scan codes voluntarily. This enhances medical insurance’s ability to monitor drug usage and protect the safety of both patients and the fund.
Can this model be replicated nationwide?
Many financial institutions are interested in implementing similar systems, but success depends on two key factors:
1. The effectiveness of the local traceability code system: If the traceability codes are not fully implemented or the data is inconsistent in other regions, banks will struggle to verify transactions.
2. Banks’ risk assessment: Banks must decide whether to adopt this model and how to assess the creditworthiness of companies involved.
The National Medical Insurance Administration is also promoting this approach, with plans to integrate traceability codes into financial credit systems by 2026. It is likely that more regions will follow suit in the future.
In summary, this innovative use of drug traceability codes has transformed them from a regulatory tool into a valuable financing mechanism. It not only helps companies overcome practical challenges but also encourages banks to provide loans and enhances medical insurance’s oversight capabilities, representing a successful and multi-beneficial initiative.